I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Pierre Fabre Labs expands R&D portfolio; announces acquisition of the worldwide rights for PFL-721 & PFL-241: Castres, France Wednesday, June 18, 2025, 11:00 Hrs [IST] Pierre Fabr ...

Real Monarchs claimed two points in dramatic fashion Saturday night, drawing 1–1 with Houston Dynamo 2 before winning the ...

Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of ...

Leerink Partners served as the exclusive financial advisor to Cogent on the term loan financing.

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for Merck and Daiichi Sankyo's ADC.

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

“Despite an evolving treatment landscape, patients with non-small cell lung cancer with EGFR exon 20 insertion mutations continue to have limited treatment options and poor disease outcomes ...

CESTBiocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation TestMechelen, Belgium, 02 June 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, is ...

The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation ...